Ceradyne (CRDN) announced that its preliminary sales figure for 2009 is approximately $401 million. These full year preliminary results compare to the guidance given on October 27, 2009 of sales in a range of $410 million to $415 million. The company noted that full year earnings are estimated to meet or slightly exceed the current guidance of approximately $0.60 per share which do not include the impact of restructuring and impairment charges for all of 2009 of approximately $0.55 per share.
Further, the company reiterated its 2010 guidance, initially provided on October 27, 2009, of a sales range of $380 million to $430 million and an earnings range of $0.60 to $1.05 per share.
Analysts expect the company to report earnings of $0.75 per share, on revenues of $391.01 million. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.